Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MTI-31 |
Synonyms | |
Therapy Description |
MTI-31 (LXI-15029) inhibits mTORC1/2, potentially resulting in decreased tumor cell proliferation and tumor growth (PMID: 30796032). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MTI-31 | LXI-15029|LXI15029|SCC-31 | mTOR Inhibitor 51 | MTI-31 (LXI-15029) inhibits mTORC1/2, potentially resulting in decreased tumor cell proliferation and tumor growth (PMID: 30796032). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
EML4 - ALK | lung non-small cell carcinoma | sensitive | MTI-31 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, MTI-31 inhibited proliferation and migration and increased PD-L1 degradation in a non-small cell lung cancer cell line harboring EML4-ALK in culture, and inhibited tumor growth in xenograft models (PMID: 30796032). | 30796032 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|